华东医药
(000963)
| 流通市值：466.65亿 | | | 总市值：466.84亿 |
| 流通股本：17.53亿 | | | 总股本：17.54亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 33,019,105,609.31 | 22,066,646,185.69 | 11,183,450,824.27 | 43,612,009,891.02 |
| 营业总成本 | 29,684,220,178.61 | 19,835,882,521.19 | 9,992,872,896.34 | 39,388,881,033.06 |
| 其他经营收益 | | | | |
| 营业利润 | 3,342,797,714.89 | 2,257,975,694.46 | 1,200,032,835.82 | 4,107,892,890.83 |
| 利润总额 | 3,261,414,596.34 | 2,210,993,063.88 | 1,192,194,345.93 | 4,016,462,310.24 |
| 净利润 | 2,748,483,940.49 | 1,839,889,537.26 | 997,161,400.38 | 3,410,846,772.45 |
| 每股收益 | | | | |
| 其他综合收益 | -192,636,630.73 | -202,374,761.11 | -80,607,620.61 | 56,368,891.24 |
| 综合收益总额 | 2,555,847,309.76 | 1,637,514,776.15 | 916,553,779.77 | 3,467,215,663.69 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 21,601,715,443.09 | 21,614,147,649.45 | 21,804,215,872.95 | 21,227,344,934.47 |
| 非流动资产: | | | | |
| 非流动资产合计 | 18,475,241,654.82 | 18,361,334,106.36 | 18,103,826,691.99 | 17,810,691,386.45 |
| 资产总计 | 40,076,957,097.91 | 39,975,481,755.81 | 39,908,042,564.94 | 39,038,036,320.92 |
| 流动负债: | | | | |
| 流动负债合计 | 13,255,437,828.36 | 13,429,764,566.07 | 13,033,135,267.46 | 13,090,663,656.22 |
| 非流动负债: | | | | |
| 非流动负债合计 | 749,646,969.73 | 765,556,304.02 | 787,195,534.95 | 776,366,984.52 |
| 负债合计 | 14,005,084,798.09 | 14,195,320,870.09 | 13,820,330,802.41 | 13,867,030,640.74 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 25,749,870,534.55 | 25,441,362,923.69 | 25,733,074,032.1 | 24,811,339,992.99 |
| 股东权益合计 | 26,071,872,299.82 | 25,780,160,885.72 | 26,087,711,762.53 | 25,171,005,680.18 |
| 负债和股东权益合计 | 40,076,957,097.91 | 39,975,481,755.81 | 39,908,042,564.94 | 39,038,036,320.92 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 35,286,972,542.73 | 23,867,508,160.06 | 10,503,828,372.21 | 48,473,910,236.87 |
| 经营活动现金流出小计 | 33,426,190,285.1 | 21,368,088,629.43 | 11,356,164,134.84 | 44,228,305,865.7 |
| 经营活动产生的现金流量净额 | 1,860,782,257.63 | 2,499,419,530.63 | -852,335,762.63 | 4,245,604,371.17 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 107,424,865.95 | 105,309,685.81 | 74,063.51 | 106,264,743.31 |
| 投资活动现金流出小计 | 926,015,055.5 | 867,916,227.46 | 391,474,414.77 | 1,776,037,156.15 |
| 投资活动产生的现金流量净额 | -818,590,189.55 | -762,606,541.65 | -391,400,351.26 | -1,669,772,412.84 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 2,429,007,007.27 | 1,739,007,007.27 | 1,132,488,831.32 | 4,240,271,213.39 |
| 筹资活动现金流出小计 | 4,257,589,891.05 | 2,722,963,960.54 | 1,097,276,837.13 | 7,062,742,873.33 |
| 筹资活动产生的现金流量净额 | -1,828,582,883.78 | -983,956,953.27 | 35,211,994.19 | -2,822,471,659.94 |
| 汇率变动对现金及现金等价物的影响 | -11,323,718.98 | -1,458,952.03 | -4,179,294.34 | -7,589,821.17 |
| 现金及现金等价物净增加额 | -797,714,534.68 | 751,397,083.68 | -1,212,703,414.04 | -254,229,522.78 |
| 期末现金及现金等价物余额 | 3,938,207,129.22 | 5,487,318,747.58 | 3,523,218,249.86 | 4,735,921,663.9 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 751,397,083.68 | - | -254,229,522.78 |
最新报告期：2026-10-30| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 华泰证券 | 代雯,李奕玮 | 1.97 | 2.00 | 2.40 | 2026-10-30 |
| 西部证券 | 李梦园,杨天笑 | 2.09 | 2.24 | 2.41 | 2026-09-11 |
| 招商证券 | 张语馨,梁广楷,许菲菲 | 2.13 | 2.34 | 2.57 | 2026-09-08 |
| 国金证券 | 甘坛焕,马居东 | 2.14 | 2.20 | 2.46 | 2026-08-31 |
| 中金公司 | 夏璐,宋歌,张琎,朱言音 | 2.18 | 2.52 | -- | 2026-08-28 |